SUMMARY
# Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investigation
## Background and Rationale
The amyloid cascade hypothesis has dominated Alzheimer's disease (AD) research for over three decades, positing that the accumulation of amyloid-beta (Aβ) peptides, particularly Aβ42, initiates a pathological cascade leading to tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and ultimately neurodegeneration. This mechanistic framework has guided the development of numerous
METHODOLOGY NOTES
Phase 1 (Months 0-3): Recruit 240 mild cognitive impairment/early AD patients, stratified by APOE4 status and CSF p-tau181 levels. Collect baseline measurements including 18F-flortaucipir PET, 11C-PIB amyloid PET, structural MRI with DTI, plasma biomarkers (p-tau217, NfL, GFAP), and comprehensive neuropsychological testing (CDR-SB, ADAS-Cog13, MMSE). Phase 2 (Months 3-21): Randomize patients 2:1 to lecanemab (10mg/kg biweekly) versus placebo. Perform monthly cognitive assessments and plasma biomarker sampling. Conduct PET imaging at months 6, 12, and 18. Use advanced MRI sequences (7T when available) to measure microglial activation (TSPO-PET), synaptic density (11C-UCB-J PET), and white matter integrity. Phase 3 (Months 18-24): Primary endpoint assessment with repeat comprehensive testing battery. Perform single-cell RNA sequencing on CSF cells to characterize microglial phenotypes. Correlate amyloid clearance rates with tau propagation patterns using network-based tau-PET analysis. P